Volume 29, Number 3—March 2023
Dispatch
Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April–June 2022
Irina Kislaya
, Aryse Melo, Marta Barreto, Camila Henriques, Carlos Aniceto, Carla Manita, Sara Ramalhete, João Almeida Santos, Sofia Soeiro, Ana Paula Rodrigues, and ISN4COVID-19 Group1
, Aryse Melo, Marta Barreto, Camila Henriques, Carlos Aniceto, Carla Manita, Sara Ramalhete, João Almeida Santos, Sofia Soeiro, Ana Paula Rodrigues, and ISN4COVID-19 Group1
Table 2
Geometric mean of specific antibodies against SARS-CoV-2 spike protein IgG, stratified by patient sex, age group, and region of residence, Portugal, April 27–June 8, 2022*
| Characteristic | Geometric mean, AU/mL (95% CI ) |
|---|---|
| Sex | |
| M | 4,344.8 (3,909.5–4,828.6) |
| F |
4,662.3 (4,150.5–5,237.1) |
| Age group, y | |
| 0–4 | 180.4 (118.9–273.6) |
| 5–9 | 426.6 (285.4–637.7) |
| 10–19 | 4,750.8 (3,795.5–5,946.5) |
| 20–29 | 6,011.5 (5,050.5–7,155.4) |
| 30–39 | 5,433.3 (4,342.8–6,797.6) |
| 40–49 | 6,940.7 (5,645.7–8,532.9) |
| 50–59 | 7,669.3 (6,297.5–9,340.0) |
| 60–69 | 5,484.6 (4,420.3–6,805.2) |
| >70 |
4,558.5 (3,708.4–5,603.4) |
| Region of residence | |
| Norte | 5,020.5 (4,358.0–5,783.6) |
| Centro | 5,020.9 (4,158.3–6,062.4) |
| Lisboa e Vale do Tejo | 3,998.1 (3,451.9–4,630.9) |
| Alentejo | 5,038.9 (4,177.2–6,078.3) |
| Algarve | 2,970.2 (2,294.2–3,845.3) |
| Madeira | 5,070.6 (4,188.3–6,138.8) |
| Açores |
4,339.1 (3,523.1–5,344.1) |
| Positivity for nucleocapsid IgG | |
| Positive | 9,233.6 (8,099.1–10,527.0) |
| Negative | 3,452.8 (3,146.7–3,788.6) |
*ISN4COVID-19 study. Weighted to match the distribution of the resident population of Portugal (Census 2021) by sex, age group, and region.
1Group members are listed at the end of this article.
Page created: January 12, 2023
Page updated: February 20, 2023
Page reviewed: February 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.